Y-mAbs claims FDA OK for neuroblastoma drug DanyelzaY-mAbs Therapeutics has claimed its first product approval, getting a green light from the FDA for Danyelza for Share XY-mAbs claims FDA OK for neuroblastoma drug Danyelzahttps://pharmaphorum.com/news/y-mabs-claims-fda-ok-for-neuroblastoma-drug-danyelza/
Lilly to ship COVID-19 drug straight away after FDA green lightEli Lilly has said it will start shipping supplies of its COVID-19 drug bamlanivimab immediately, after claiming emergency-use Share XLilly to ship COVID-19 drug straight away after FDA green lighthttps://pharmaphorum.com/news/lilly-to-ship-covid-19-drug-straight-away-after-fda-green-light/
Regeneron’s COVID-19 antibody cocktail therapy hits safety problemRegeneron’s coronavirus antibody cocktail therapy against COVID-19, famously used to treat president Donald Trump, has hit a safety Share XRegeneron’s COVID-19 antibody cocktail therapy hits safety problemhttps://pharmaphorum.com/news/regenerons-covid-19-antibody-cocktail-therapy-hits-safety-problem/
US buys Lilly COVID antibody, as effectiveness questions remainThe US government said it will buy 300,000 doses of Eli Lilly’s COVID-19 therapy bamlanivimab for $375 million Share XUS buys Lilly COVID antibody, as effectiveness questions remainhttps://pharmaphorum.com/news/us-buys-300000-doses-lilly-covid-antibody/
NIAID drops Lilly antibody from ACTIV-3 COVID-19 trialEli Lilly says no more patients will be treated with its COVID-19 therapy bamlanivimab in a trial run Share XNIAID drops Lilly antibody from ACTIV-3 COVID-19 trialhttps://pharmaphorum.com/news/niaid-drops-lilly-antibody-from-activ-3-covid-19-trial/
Regeneron joins Lilly in seeking emergency OK for COVID-19 antibodyRegeneron has followed Eli Lilly in asking the FDA for emergency approval of its COVID-19 antibody therapy, shortly Share XRegeneron joins Lilly in seeking emergency OK for COVID-19 antibodyhttps://pharmaphorum.com/news/regeneron-joins-lilly-in-seeking-emergency-ok-for-covid-19-antibody/
BioNTech, Lilly shore up manufacturing capacity for their COVID-19 medsWith vaccines and drugs for COVID-19 now in late-stage development, companies are moving swiftly to lay down the Share XBioNTech, Lilly shore up manufacturing capacity for their COVID-19 medshttps://pharmaphorum.com/news/biontech-lilly-shore-up-manufacturing-capacity-for-their-covid-19-meds/
Eyeing emergency use of COVID-19 drug, Humanigen partners with Lonza to make itHumanigen is hoping for emergency use authorisation in the US for an antibody to treat severe COVID-19 before Share XEyeing emergency use of COVID-19 drug, Humanigen partners with Lonza to make ithttps://pharmaphorum.com/news/eyeing-emergency-use-of-covid-19-drug-humanigen-partners-with-lonza-to-make-it/
Chasing Regeneron, AZ starts trials of its COVID-19 antibody cocktailThe first patients have been dosed in a trial of two AstraZeneca antibodies, collectively known as AZD7442, that Share XChasing Regeneron, AZ starts trials of its COVID-19 antibody cocktailhttps://pharmaphorum.com/news/chasing-regeneron-az-starts-trials-of-its-covid-19-antibody-cocktail/
